3-Dimensional Pharmaceuticals thrombin inhibitor deal with Wyeth carries maximum value of $112 mil..
Executive Summary
3-DIMENSIONAL PHARMACEUTICALS IPO WITHIN TWELVE MONTHS is planned by the Exton, Penn. company. The drug discovery firm is currently talking to investment bankers about an initial public offering and will be preparing an S-1 registration statement for the Securities & Exchange Commission in the near future, 3DP said. The company reports current cash resources of about $15 mil., sufficient to fund two to three years of operations. 3DP completed a $12.5 mil. round of equity financing in March, led by Rho Management.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth